Skip to content

Osteopathy and Obstructive Sleep Apnea Syndrome

a Single Blind Cross Over Trial to Compare Osteopathic Compression of Pterygopalatine Node to Placebo Compression in Obstructive Sleep Apnea Syndrome.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01193738
Enrollment
10
Registered
2010-09-02
Start date
2010-09-30
Completion date
2012-01-31
Last updated
2015-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea Syndrome

Keywords

osteopathy

Brief summary

The main objective is to evaluate an osteopathic compression of pterygopalatine node on sleep obstructive apnea syndrome (OSA).

Detailed description

Osteopathic compression will be compared to a placebo manoeuvre. Efficacy will be assessed by measuring pharyngeal collapsibility

Interventions

PROCEDUREosteopathic compression of Pterygopalatine node

osteopathic compression of Pterygopalatine node

Sponsors

Valerie Attali
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or Female aged 18 years or more * obstructive sleep apnea syndrome with apnea/hypopnea index \> or = 15/hour * Body mass Index \<40kg/m2

Exclusion criteria

* pregnant or lactating women * participating to another trial * acute infectious disease of upper respiratory airway tract at inclusion * facial neuralgia at inclusion * patients not able to stop treatment for OSA within one week before each visit * allergy to latex * dental extraction within 15 days before inclusion * pharyngeal surgery in the past * incapable adult

Design outcomes

Primary

MeasureTime frameDescription
pharyngeal critical pressure30 minutes after osteopathic compressionThe collapsibility of the upper airway will be evaluated by pharyngeal critical pressure,assessed by measuring the intraluminal pressure associated with the cessation of airflow

Secondary

MeasureTime frameDescription
pharyngeal critical pressure48 hoursThe collapsibility of the upper airway will be evaluated by pharyngeal critical pressure,assessed by measuring the intraluminal pressure associated with the cessation of airflow
symptoms48 hoursOSA symptoms
adverse events48 hoursclinical evaluation of adverse events

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026